Clinicopathological Role of Serum-Derived Hyaluronan-Associated Protein (SHAP)-Hyaluronan Complex in Endometrial Cancer

Table 7

Hazard ratios for overall survival with 95%CIs adjusted for HAS, HA, SHAP-HA complex, UTI, MMP-2, MMP-9, TIMP-1, and the clinicopathological manifestations in patients with endometrial cancer.

Variables	Hazard ratio	95% CI	𝑃 value
Age	0.848	0.583–1.232	0.3859
Myometrial invasion (more than half)	3.846	0.027–544.845	0.5940
Histological grade (G3)	0.007	<0.001–7458.166	0.4799
Lymph-vascular space involvement	0.002	<0.001–175.169	0.2913
HAS1 expression	—	—	—
HAS2 expression	—	—	—
HAS3 expression	—	—	—
HA	1.003	0.984–1.023	0.7456
SHAP-HA complex	3.417	0.820–12.075	0.0947
UTI	0.297	0.055–1.610	0.1591
MMP-2	1.010	0.992–1.029	0.2790
MMP-9	1.004	0.996–1.013	0.3126
TIMP-1	—	—	—